Citizens Business Bank Has $423,000 Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Citizens Business Bank grew its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,222 shares of the biopharmaceutical company’s stock after purchasing an additional 301 shares during the period. Citizens Business Bank’s holdings in Gilead Sciences were worth $423,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Nilsine Partners LLC boosted its stake in Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after buying an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. increased its stake in Gilead Sciences by 0.7% in the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the period. Financial Counselors Inc. raised its position in Gilead Sciences by 1.5% in the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after purchasing an additional 128 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC boosted its holdings in Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after purchasing an additional 140 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Down 1.1 %

Gilead Sciences stock traded down $0.74 during mid-day trading on Tuesday, hitting $65.20. The stock had a trading volume of 7,433,077 shares, compared to its average volume of 7,480,851. The stock has a market capitalization of $81.18 billion, a PE ratio of 181.14, a P/E/G ratio of 1.29 and a beta of 0.19. Gilead Sciences, Inc. has a 12 month low of $64.63 and a 12 month high of $87.86. The company has a current ratio of 0.98, a quick ratio of 0.72 and a debt-to-equity ratio of 1.08. The stock has a 50-day simple moving average of $71.16 and a two-hundred day simple moving average of $76.17.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.17. Gilead Sciences had a net margin of 1.76% and a return on equity of 24.34%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter last year, the firm earned $1.37 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, sell-side analysts forecast that Gilead Sciences, Inc. will post 3.82 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.72%. The ex-dividend date of this dividend is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at approximately $7,026,339.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.29% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Oppenheimer restated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a research report on Friday, April 19th. Mizuho reduced their target price on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Truist Financial cut shares of Gilead Sciences from a “buy” rating to a “hold” rating and dropped their target price for the stock from $91.00 to $82.00 in a research report on Thursday, February 22nd. Wells Fargo & Company reduced their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Monday, March 4th. Finally, HSBC raised shares of Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price objective for the company in a report on Wednesday, April 24th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences currently has a consensus rating of “Hold” and an average price target of $83.60.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.